Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings (in partnership with medwireNews).

Login and start reading, or Join ESMO

Filter by:

80 results

Anticancer Agents;  Non-Small Cell Lung Cancer

DUBLIN-3: Plinabulin–Docetaxel Improves Advanced NSCLC Outcomes

From the ESMO Congress 2021:
Plinabulin plus docetaxel survival and safety results support second- or third-line use in non-small-cell lung cancer patients with wild-type EGFR after platinum-based chemotherapy

Non-Small Cell Lung Cancer;  Radiation Oncology

Lung ART: Nodal Burden Best Guide For Predicting PORT Benefit

From the ESMO Congress 2021:
Nodal burden may help identify patients with resected stage III non-small-cell lung cancer who may derive some benefit from postoperative conformal radiotherapy

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.